Donald Trump’s proposed 200% tariff on generic drug imports is less a blow to India’s pharmaceutical industry than a costly gamble that could leave American patients paying the highest price.
The slim chance that a female athlete will be disadvantaged by a transgender person over the course of her athletic career is out of proportion to the intensity of the debate.